公开(公告)号：US20220241263A1

公开(公告)日：2022-08-04

申请号：US17615735

申请日：2020-05-29

Applicant: Ares Trading S.A. ,  Pfizer Inc.

Inventor： Marat Alimzhanov ,  Keith Anthony Ching ,  Alessandra Di Pietro ,  Xinmeng Mu ,  Paul Brian Robbins

IPC: A61K31/4439 ,  A61K39/395 ,  C07K16/28 ,  A61P35/00

Abstract: The present disclosure describes combination therapies comprising a PD-1 axis binding antagonist, wherein the cancer has been pre-determined to have one or more genetic mutations in one or more genes, to have certain gene expression profiles, and/or to have other biomarkers.

公开(公告)号：US20230250173A1

公开(公告)日：2023-08-10

申请号：US18002942

申请日：2021-06-29

Applicant: Pfizer Inc.

Inventor： Keith Anthony Ching ,  Craig Davis ,  Xinmeng Mu ,  Shobha Potluri ,  Yan Qu ,  Shahram Salek-Ardakani ,  Graham Thomas ,  Ji Wen

IPC: C07K16/28 ,  C12Q1/6886 ,  A61P35/00 ,  A61P13/02

CPC classification number: C07K16/2818 ,  C12Q1/6886 ,  A61P35/00 ,  A61P13/02 ,  C12Q2600/106 ,  C12Q2600/158

Abstract: The present disclosure describes therapies comprising a PD-1 axis binding antagonist, wherein a sample from the patient has been pre-determined to have certain biomarkers.